Latest news - Page 7 of 8 - Explicyte Immuno-Oncology

By charles_lbs21 May 20193 June 2024

Explicyte intensifies its efforts in translational research & will attend the next ASCO Annual Meeting

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.

explicyte immuno-oncology bergonie institut cancer centrer cro translational

By charles_lbs25 March 20193 June 2024

Explicyte and Institut Bergonié partner for comprehensive translational research programs in immuno-oncology

Explicyte and Institut Bergonié have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.

By charles_lbs20 March 20193 June 2024

Explicyte will be attending the AACR Annual Meeting 2019 in Atlanta

We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

By charles_lbs13 March 20194 June 2024

M2 Macrophage Suppression Assay

Our newly validated M2 suppression assay is specifically designed to assess new immunotherapeutics for their modulatory activity on the phenotype and function of M2 macrophages.

immune profiling syngeneic tumor models services CRO

By charles_lbs20 February 20193 June 2024

Intratumoral microdialysis-based approach to assess tumor immunometabolism & specific immunometabolic pathways-targeting

Syngeneic tumor models are becoming invaluable for preclinical development and evaluation of immuno-based therapies. They are primordial for tumor model characterization and selection of the appropriate ones, for target validation, drug development, and assessment of the efficacy potential of drug candidates.

Take Part Of The Next Anti-CTLA4 Explicyte Shuttle

By charles_lbs17 January 20194 June 2024

In vivo syngeneic subcutaneous tumor models for cost-saving efficacy studies

Explicyte is planning a new in vivo shuttle session by early March, thereby providing an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic subcutaneously-implanted tumor models.

chemotaxis assay neutrophils cancer immunotherapy CRO

By charles_lbs6 December 20183 June 2024

Neutrophil chemotaxis assay for cancer immunotherapy screening

Explicyte set up and validated a robust real-time neutrophil migration assay, which allows for time-lapse monitoring and analysis of chemotactic driven neutrophil migration across an optically clear filter membrane.

By charles_lbs17 May 20184 June 2024

Eurostars Granted Project. A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours

Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.

By charles_lbs28 February 20184 June 2024

New In Vivo Syngeneic Mammary Fat Pad Mouse Model Shuttle Session

In view of the success of our previous shuttle sessions, which offered the opportunity to run efficacy studies in a cost-saving manner, we are planning a new shuttle on the orthotopic (OT) 4T1 mammary fat pad mouse model, which will be held in late March.

By charles_lbs19 February 20183 June 2024

In Vitro Immune Cell Activation

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.

By charles_lbs24 January 20184 June 2024

Combination Of In Vivo Efficacy Monitoring With Intratumoral Biopsy To Assess New Cancer Therapies & Decipher Their MoA

Explicyte is proud to announce the recent development and validation of our new syngeneic subcutaneously-implanted MCA-205 sarcoma tumor mouse model.

By charles_lbs16 October 20173 June 2024

Immunosuppressive Tumor Microenvironment In OT 4T1 Breast Tumor Model

While known and validated as non-responsive to conventional immune checkpoint inhibitors, our OT syngeneic mammary tumor model, which represents an aggressive model of human breast carcinoma, is characterized by the presence of at least two types of tumor-infiltrating immunosuppressive cells – myeloid suppressive cells (MSC) and T regulatory cells (Treg).

Previous page 1 … 5 6 7 8 Next page